Cargando…

Carbamazepine drug reaction involving high fevers during the COVID-19 era

Carbamazepine has demonstrated anticonvulsant properties and is used for a variety of indications in psychiatry and neurology. Total daily doses typically range from 200 to 1200 mg/d, generally divided into 2 doses. Carbamazepine has a broad side-effect profile but is not typically thought to produc...

Descripción completa

Detalles Bibliográficos
Autores principales: Heyman-Kantor, Reuben, Perez, Matthew, Phatak, Arti, Anderson, Danielle L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463002/
https://www.ncbi.nlm.nih.gov/pubmed/34621604
http://dx.doi.org/10.9740/mhc.2021.09.287
_version_ 1784572317360193536
author Heyman-Kantor, Reuben
Perez, Matthew
Phatak, Arti
Anderson, Danielle L
author_facet Heyman-Kantor, Reuben
Perez, Matthew
Phatak, Arti
Anderson, Danielle L
author_sort Heyman-Kantor, Reuben
collection PubMed
description Carbamazepine has demonstrated anticonvulsant properties and is used for a variety of indications in psychiatry and neurology. Total daily doses typically range from 200 to 1200 mg/d, generally divided into 2 doses. Carbamazepine has a broad side-effect profile but is not typically thought to produce high fevers in the absence of a hypersensitivity syndrome. This is a case of a probable adverse drug reaction to carbamazepine consisting of fever without severe major organ involvement. In this instance, a patient in a manic episode with psychotic features was briefly transferred to a COVID-19 unit to rule out coronavirus infection before the fever resolved.
format Online
Article
Text
id pubmed-8463002
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher College of Psychiatric & Neurologic Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-84630022021-10-06 Carbamazepine drug reaction involving high fevers during the COVID-19 era Heyman-Kantor, Reuben Perez, Matthew Phatak, Arti Anderson, Danielle L Ment Health Clin Case Reports Carbamazepine has demonstrated anticonvulsant properties and is used for a variety of indications in psychiatry and neurology. Total daily doses typically range from 200 to 1200 mg/d, generally divided into 2 doses. Carbamazepine has a broad side-effect profile but is not typically thought to produce high fevers in the absence of a hypersensitivity syndrome. This is a case of a probable adverse drug reaction to carbamazepine consisting of fever without severe major organ involvement. In this instance, a patient in a manic episode with psychotic features was briefly transferred to a COVID-19 unit to rule out coronavirus infection before the fever resolved. College of Psychiatric & Neurologic Pharmacists 2021-09-24 /pmc/articles/PMC8463002/ /pubmed/34621604 http://dx.doi.org/10.9740/mhc.2021.09.287 Text en © 2021 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Heyman-Kantor, Reuben
Perez, Matthew
Phatak, Arti
Anderson, Danielle L
Carbamazepine drug reaction involving high fevers during the COVID-19 era
title Carbamazepine drug reaction involving high fevers during the COVID-19 era
title_full Carbamazepine drug reaction involving high fevers during the COVID-19 era
title_fullStr Carbamazepine drug reaction involving high fevers during the COVID-19 era
title_full_unstemmed Carbamazepine drug reaction involving high fevers during the COVID-19 era
title_short Carbamazepine drug reaction involving high fevers during the COVID-19 era
title_sort carbamazepine drug reaction involving high fevers during the covid-19 era
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463002/
https://www.ncbi.nlm.nih.gov/pubmed/34621604
http://dx.doi.org/10.9740/mhc.2021.09.287
work_keys_str_mv AT heymankantorreuben carbamazepinedrugreactioninvolvinghighfeversduringthecovid19era
AT perezmatthew carbamazepinedrugreactioninvolvinghighfeversduringthecovid19era
AT phatakarti carbamazepinedrugreactioninvolvinghighfeversduringthecovid19era
AT andersondaniellel carbamazepinedrugreactioninvolvinghighfeversduringthecovid19era